As advised via PHARMAC Tender Results of 31 May 2019 there is to be a change in the listing and future sole supply of Droperidol Injection.

New listing from 1 December 2019 HML only

Droleptan Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack                                   Pharmacode 727253                      Schedule price $30.95

Incumbent brand

Droperidol Panpharma Inj 2.5 mg per ml, 1 ml ampoule; 10 ampoule pack          Pharmacode TBA                                     Schedule price $35.00

HSS (Hospital Supply Status) commences 1 May 2020.

As of the date of this notification ProPharma / PWR cannot accept Droperidol Panpharma Inj for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 May 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 May 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author